colleagues at the Texas Medical Center in Houston.
1 Surprisingly, the initial National Institute of Neurological Disorders and Stroke (NINDS) tissue plasminogen activator (tPA) study results did not seem to reflect this relationship. But once it was recognized that patients with the most severe strokes presented to the emergency department (ED) earlier and stroke severity was factored into the calculation, it became clear that the sooner tPA was given, the better the clinical response to tPA. 2 The same relationship exists with endovascular mechanical reperfusion, 3 and probably efforts to reduce bleeding by blood pressure lowering or coagulopathy reversal after intracerebral hemorrhage.
While the use of tPA is increasing (now 5-10 % of all stroke patients;
10-20 % in most stroke centers), treatment usually occurs 2-5 hours after symptom onset even if patients or bystanders do the right thing and call 911. 4 In the NINDS study, none of the 302 patients who were randomized within the first 90 minutes actually were treated within the first 60 minutes from onset. 5 Current national databases show that less than 5 % of treatments occur in the first hour. 4 The delay is multifactorial and includes delay in calling 911, mobilizing emergency medical services (EMS) and transporting patients to the right ED, and, finally, the ED door to needle time, which stubbornly averages 50-60 minutes in even our best stroke centers, largely taken up by time to obtain the CT scan and having the decision-maker (usually the neurologist on call) look at it and make a decision after weighing all the variables.
The MSU cuts out the entire door-to-needle-time delay by putting the CT scanner and decision-maker on the ambulance. The initial studies conducted in Germany and published over the past 2 years demonstrated anywhere from 25-80 minute time savings, and over 30 % treated within the first hour after symptom onset, without excess complications. Medical Services (BEST-MSU) study was approved by the UT-Houston IRB on January 11, 2013 to address these aims and is registered with clinicaltrials.gov (NCT02190500).
We began fundraising in March 2013 eventually raising $1. 
